Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine

Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine

BERKELEY, CA, Jul 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the award of a $600,000 grant from the National Institutes of Health (NIH) to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus (HPV). In contrast to the two approved HPV vaccines that target approximately 70 percent of HPV strains, Dynavax's goal is to develop a vaccine that provides immunity to nearly all cancer-causing strains of HPV. Each year, 470,000 cervical cancers are diagnosed worldwide, and 250,000 deaths are due to cervical cancers.

About Dynavax Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV(TM), an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Michael Ostrach
Vice President and Chief Business Officer
Email Contact

SOURCE: Dynavax Technologies


Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX


Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.